The Institute for Clinical and Economic Review (ICER) has released a white paper that articulates a vision for health technology assessment (HTA) aimed at mitigating healthcare disparities. This comprehensive document outlines strategies to enhance health equity, particularly for vulnerable populations in the United States.
HTA plays a critical role in evaluating new medical technologies, including drugs and surgical devices. It provides essential data that informs decisions made by insurers and policymakers regarding coverage, pricing, and reimbursement. The white paper titled “Advancing Health Technology Assessment Methods that Support Health Equity” critically examines existing HTA methodologies and identifies areas needing improvement from an equity perspective.
Goals of HTA in Addressing Health Disparities
The primary objective of the white paper is to ensure that HTA processes contribute to reducing disparities in healthcare access and outcomes for racial, ethnic, and socially disadvantaged groups. The authors emphasize that as the nation grapples with its historical issues of racism and discrimination, it is essential to reassess the ethical frameworks underpinning HTA methodologies.
The recommendations put forth target a diverse audience, including HTA agencies, life sciences companies, clinical researchers, patient advocacy groups, and insurers. Each group plays a pivotal role in integrating equity considerations into their operations and decision-making processes.
Formalizing Equity Assessment
A key recommendation is the establishment of formal processes to incorporate health equity into the selection of topics for HTA. This means that interventions should be evaluated not only for general effectiveness but also for their impact on specific populations that may suffer disproportionately from certain health conditions.
The authors advocate for improved engagement with patients and community groups during the HTA process. This engagement can provide valuable insights into the real-world effects of interventions, particularly for conditions that disproportionately affect specific demographics.
Enhancing Patient Engagement
To foster meaningful patient involvement, the white paper suggests various strategies. These include connecting with patient networks to capture diverse perspectives, ensuring that informational materials are accessible to all communities, and leveraging social media to gather broad patient insights. Additionally, forming diverse advisory groups can provide ongoing input into HTA processes.
Evaluating Clinical Trial Diversity
Another critical aspect of the recommendations focuses on the evaluation of diversity within clinical trial populations. The authors advocate for a systematic approach to assess representation across racial and ethnic categories during the HTA process. This evaluation should not only reflect the demographics of the U.S. population but also take into account the epidemiology of specific conditions to ensure the appropriate populations are represented in clinical trials.
The authors propose establishing minimum thresholds for diversity in clinical trials, along with an overall diversity rating scale. This scale would include assessments of subpopulations to enhance the granularity of representation metrics.
Addressing Opportunities for Disparity Reduction
When assessing interventions with the potential to reduce existing health disparities, HTA processes should prioritize these evaluations. However, the decision-making often lacks empirical evidence. The authors recommend enhancing the data collection processes to measure equity impacts effectively.
Decision-makers need access to information regarding the prevalence of conditions within subpopulations and relevant data that could highlight potential disparities that an innovation might address. Given the multifaceted nature of health disparities, the authors caution against relying on single metrics for decision-making.
Rethinking Economic Evaluations
The white paper also calls for a re-examination of economic evaluations, such as cost-effectiveness analyses. The authors propose developing equity-informative economic evaluation methods that can explore the distributional impacts of healthcare treatments. These methods can provide a richer understanding of how interventions affect various demographics.
However, they warn that demonstrating potential disparities reduction should not be used as justification for increasing treatment costs, as this would counteract the goal of improving access to care.
Integrating Equity into HTA Reports
Finally, the authors recommend implementing deliberative processes that emphasize equity-related information in HTA reports. This integration should inform value assessments and decisions regarding healthcare interventions. It is crucial to openly discuss the potential conflicts between promoting equity and mitigating disparities during decision-making processes.
ICER’s vice president of research, Foluso Agboola, underscores the necessity of aligning HTA methods with health equity considerations. He notes that decision-makers require clear insights into how evidence can inform equitable pricing and coverage decisions.
Key Takeaways
- HTA must prioritize health equity to address disparities affecting vulnerable populations.
- Engaging patients and diverse groups in the HTA process is essential for capturing nuanced insights.
-
Clinical trial diversity must be rigorously evaluated to ensure representative populations are studied.
-
Economic evaluations should be redefined to incorporate equity impacts alongside traditional cost-effectiveness metrics.
-
Transparency and deliberation regarding equity considerations are vital in the HTA process.
In conclusion, the ICER white paper presents a vital framework for advancing health technology assessments to promote equity in healthcare. By adopting these recommendations, stakeholders can work collaboratively to ensure that healthcare innovations are accessible to all, thereby fostering a more equitable healthcare landscape.
Read more → www.ajmc.com